Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Aug:1321:41-54.
doi: 10.1111/nyas.12499.

Antibody-drug conjugates: an emerging modality for the treatment of cancer

Mauricio Leal  1 , Puja Sapra, Sara A Hurvitz, Peter Senter, Alan Wahl, Melissa Schutten, Dhaval K Shah, Nahor Haddish-Berhane, Omar Kabbarah
Affiliations
Review

Antibody-drug conjugates: an emerging modality for the treatment of cancer

Mauricio Leal et al. Ann N Y Acad Sci. 2014 Aug.

Abstract

Antibody-drug conjugates (ADCs) offer promise as a therapeutic modality that can potentially reduce the toxicities and poor therapeutic indices caused by the lack of specificity of conventional anticancer therapies. ADCs combine the potency of cytotoxic agents with the target selectivity of antibodies by chemically linking a cytotoxic payload to an antibody, potentially creating a synthetic molecule that will deliver targeted antitumor therapy that is both safe and efficacious. The ADC repertoire contains a range of payload molecules, antibodies, and linkers. Two ADC molecules, Kadcyla® and Adcetris®, have been approved by the FDA, and many more are currently in clinical development.

Keywords: antibody-drug conjugate; cancer therapy; linker; payload; quantitative translational systems pharmacology.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

MeSH terms

LinkOut - more resources